Susquehanna International Group
XBIO icon

Susquehanna International Group’s Xenetic Biosciences XBIO Stock Holding History

Susquehanna International Group’s Portfolio XBIO Stock Details XBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,380
Closed -$186K – 14102
2021
Q4 		$186K Buy
+14,380
New +$229K ﹤0.01% 11536

Other funds holding XBIO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
LGF
LGT Group Foundation Vaduz, Liechtenstein $8.19B AUM 27.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWM
Darwin Wealth Management Tampa, Florida $365M AUM 22.69% 1-Year Est. Return

Susquehanna International Group's XBIO Position: Q2 2025 in Review

Susquehanna International Group sold out of Xenetic Biosciences (XBIO) in Q2 2025, closing a stake of 25,388 shares — an estimated $66.3K sold.

Susquehanna International Group first reported a position in XBIO in Q3 2019 and held it in 7 quarters. The position peaked at $164K in Q4 2021. 9 funds tracked by Wall St. Rank hold XBIO as of Q2 2025.

  • Susquehanna International Group reported no remaining Xenetic Biosciences position as of Q2 2025 after selling out during the quarter.
  • Susquehanna International Group sold 25,388 Xenetic Biosciences shares in Q2 2025, an estimated $66.3K.
  • Susquehanna International Group first reported a position in Xenetic Biosciences in Q3 2019 and held it in 7 quarters.
  • Susquehanna International Group's Xenetic Biosciences position peaked at $164K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Xenetic Biosciences as of Q2 2025.

Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.